Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency SUR Cancer Info Ctr Missing | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library | Available |
Contents:; 1. Mechanism of Chemotherapy in Cancer Treatment -- 2. Neutropenic Complications of Chemotherapy -- 3. Chemotherapy Induced Anemia -- 4. Cancer Treatment Related Thrombocytopenia -- 5. Oral Mucositis -- 6. Gastrointestinal Complications of Chemotherapy -- 7. Neurological Complications --…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.3 BC Cancer Agency KEL Cancer Info Ctr Missing | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24-31 May 2016
Table of Contents available at link.
PART I: INTRODUCTION AND BACKGROUND; 1 INTRODUCTION; 2 CANNABIS; 3 CANNABIS: PREVALENCE OF USE, REGULATION, AND CURRENT POLICY LANDSCAPE; PART II: THERAPEUTIC EFFECTS; 4 THERAPEUTIC EFFECTS OF CANNABIS AND CANNABINOIDS; PART III: OTHER HEALTH EFFECTS; 5 CANCER; 7 RESPIRATORY DISEASE; 8 IMMUNITY; 9…